Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
16 United States sites
3 Canada sites
18 Years - 50 Years
Phase 1/Phase 2
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
49 United States sites
5 France sites
5 Spain sites
4 Greece sites
4 Italy sites
4 United Kingdom sites
3 Canada sites
2 Lebanon sites
2 Germany sites
12 Years - 65 Years
Phase 2/Phase 3
This study is evaluating a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
4 United States sites
1 Italy site
2 Years - 40 Years
HbSS, HbSC
Phase 1/Phase 2
This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD).
1 United States site
2 Years - 25 Years
Phase 2
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients.
4 United States sites
5 Years - 50 Years
SCA, HbSS
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.
17 United States sites
5 Nigeria sites
4 Egypt sites
4 Kenya sites
4 United Kingdom sites
3 Italy sites
2 Ghana sites
2 Oman sites
2 Saudi Arabia sites
1 France site
2 Years - 14 Years
SCA
Phase 3
Children with sickle cell disease (SCD) are living longer with the advent of medical advances such as prophylactic penicillin, chronic transfusion, and hydroxyurea.
2 United States sites
16 Years - 20 Years
Recommendations for exercise prescription currently do not exist for individuals with sickle cell anemia (SCA) despite the known impact that SCA-related complications has on physical functioning and fitness.
4 United States sites
10 Years - 21 Years
hemoglobin SS
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences).
11 United States sites
1 Month - 5 Years
Not Applicable
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US.
4 United States sites
> 18 Years
SCA
